Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
April 22, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 18, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment...
Panbela Announces Transfer to OTCQB Market
April 16, 2024 17:29 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
March 26, 2024 16:10 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
March 12, 2024 16:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 15, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Closing of Approximately $9.0 Million Public Offering
February 01, 2024 07:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 30, 2024 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 29, 2024 06:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
January 25, 2024 07:00 ET
|
Panbela Therapeutics, Inc.
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company...